MOWOOT 2024

MOWOOT is an official brand of USMIMA S.L., a growth company that was created in November 2014 as part of Biocat’s MOEBIO EU Stanford Biodesign program in close collaboration with the Institut Guttmann, a leading hospital in neuro-rehabilitation.

MOWOOT has developed and initiated the commercialization of a medical device for the treatment of bowel dysfunction (BD). It is the first non-pharmacological and non-invasive solution that provides a novel and innovative solution to patients and solves a great unmet need.

MOWOOT consists of a belt connected to a tabletop device that emulates the natural contractions of the large intestine (exo-peristalsis) to facilitate intestinal transit without the adverse effects of pharmacological or invasive solutions. Furthermore, with only 20 minutes of daily use, MOWOOT has demonstrated a higher efficacy than current remedies in clinical studies. MOWOOT’s Intermittent Colonic Exoperistalsis™ therapy is inspired by professional colonic massage that is used by physiotherapists in neurorehabilitation solving an unmet need resulting from the impossibility in time and resources of having a physiotherapist perform this type of therapy on a daily basis to the millions of patients who suffer from chronic constipation.

The company is ISO 13485 certified and the product has achieved CE marking as a class IIa medical device (MDR), is clinically validated and its intellectual property is protected in the EU, USA, Canada and China. In 2021, the company successfully transitioned to the new MDR standard of CE.

MOWOOT is present in the first international markets and has sales and commercial agreements with distributors in Germany, England, Netherlands, Denmark, Peru, Thailand, Malaysia and UAE. Additional international licensing and distribution agreements are being negotiated.

Product pipeline: Preparations are currently underway for the launch of a new version of the exoperistataltic belt, even more adapted to the needs of the different international health systems ( for example in regards to cost-effectiveness) and sales channels (distributors, etc.), scheduled for 2025.

At the same time, a digital platform is being developed that allows physiological data (through the belt) and symptomatic data (through an APP) to be collected and analysed using AI and open the door to digital health and big data. This project has recently obtained €2.2 million in public funding from the Spanish Ministry of Science, Innovation and Universities within the framework of Public-Private Collaboration and is being developed in collaboration with reference centers EURECAT and IDIAPJGol.

Having raised around €6.1 million of investment in recent years, MOWOOT still has a clear leadership with 70.64% of the shares held by the founders, ensuring an agile execution of the business plan to achieve the next milestones: international expansion through marketing and licensing agreements, reimbursement by public healthcare providers in Northern European markets and the Launch of a new version of the product in 2025.

The objective of the current Bridge Funding Round is to achieve an investment of €400,000 to consolidate MOWOOT’s expansion in Europe in the short term, with a special focus on obtaining public healthcare reimbursement in England and preparing the launch of the new product in this market, while negotiating international distribution and/or licensing agreements.

With the major milestone of NHS/NICE reimbursement in England, the second largest market for medical devices in Europe, the company’s valuation will increase significantly, putting it in a very good position to negotiate a Series A investment round, a strategic collaboration and/or a future acquisition of the company by the end of 2025.

The project has the commitment and trust of investors specialized in the sector, such as GENESIS Ventures (Spain), 4M Medical GmbH (Germany) and EIT Health (Belgium) among others.

To date, these are some of the awards and recognitions that validate the company’s value.